NeuroSense Therapeutics Amends Warrant Agreement
Ticker: NRSNW · Form: 6-K · Filed: Jun 27, 2024 · CIK: 1875091
Sentiment: neutral
Topics: warrant-amendment, financing, shareholder-dilution
TL;DR
NeuroSense tweaked a warrant deal with an investor, changing redemption terms and pushing out the expiry date.
AI Summary
On June 26, 2024, NeuroSense Therapeutics Ltd. amended a warrant agreement with an institutional investor. This amendment adjusts the "Redemption Right" and extends the termination date of the 2023 Warrant, which was originally for up to 3,000,000 ordinary shares.
Why It Matters
This filing indicates a modification to an existing financial instrument, potentially impacting the company's share structure and future dilution.
Risk Assessment
Risk Level: low — The filing concerns an amendment to an existing warrant agreement, which is a common financial maneuver and does not represent a new or significant risk event.
Key Numbers
- 3,000,000 — Ordinary Shares (Maximum number of shares issuable under the 2023 Warrant)
Key Players & Entities
- NeuroSense Therapeutics Ltd. (company) — Registrant
- Investor (company) — Institutional investor party to warrant amendment
- June 26, 2024 (date) — Date of warrant amendment
- 3,000,000 (dollar_amount) — Number of ordinary shares covered by the 2023 Warrant
- June 2023 (date) — Original issuance date of the 2023 Warrant
FAQ
What specific adjustments were made to the "Redemption Right" in the 2023 Warrant?
The filing states that certain adjustments were made to the "Redemption Right" but does not specify the exact nature of these adjustments.
What is the new termination date for the 2023 Warrant?
The filing indicates the termination date was extended but does not provide the new specific date.
Who is the institutional investor party to this warrant amendment?
The filing refers to the counterparty as 'a certain institutional investor' and does not disclose their specific name.
What was the original issuance date of the 2023 Warrant?
The 2023 Warrant was originally issued in June 2023.
Does this amendment affect the number of ordinary shares NeuroSense Therapeutics Ltd. can issue?
The amendment adjusts the "Redemption Right" and extends the termination date, but the warrant remains for up to 3,000,000 ordinary shares, implying the maximum share count is unchanged unless other terms are affected.
Filing Stats: 377 words · 2 min read · ~1 pages · Grade level 11.1 · Accepted 2024-06-27 08:00:11
Filing Documents
- ea0208577-6k_neurosense.htm (6-K) — 17KB
- ea020857701ex10-1_neurosense.htm (EX-10.1) — 20KB
- ea020857701ex10-2_neurosense.htm (EX-10.2) — 15KB
- 0001213900-24-056329.txt ( ) — 53KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NeuroSense Therapeutics Ltd. Date: June 27, 2024 By: /s/ Alon Ben-Noon Alon Ben-Noon Chief Executive Officer 3